Page last updated: 2024-09-04

cositecan and Colonic Neoplasms

cositecan has been researched along with Colonic Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Boven, E; Hausheer, FH; Pinedo, HM; Schlüper, HM; Van Hattum, AH1
Boven, E; Hoogsteen, I; Pinedo, HM; Schlüper, HM; Van Hattum, AH1

Other Studies

2 other study(ies) available for cositecan and Colonic Neoplasms

ArticleYear
New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer.
    International journal of cancer, 2000, Oct-15, Volume: 88, Issue:2

    Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colonic Neoplasms; Doxorubicin; Drug Resistance, Multiple; Enzyme Inhibitors; Female; Humans; Irinotecan; Lung Neoplasms; Melanoma; Mice; Mice, Nude; Neoplasms; Ovarian Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2000
New analogues of camptothecins. Activity and resistance.
    Annals of the New York Academy of Sciences, 2000, Volume: 922

    Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Colonic Neoplasms; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2000